We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Evidence-Based Dermatology: Research Commentary |

Systemic Adjuvant Therapy for Patients With High-Risk Melanoma

Kenneth Y. Tsai, MD, PhD
Arch Dermatol. 2007;143(6):779-782. doi:10.1001/archderm.143.6.779.
Text Size: A A A
Published online


Creagan  ETDalton  RJAhmann  DL  et al.  Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;132776- 2783
Kirkwood  JMStrawderman  MHErnstoff  MSSmith  TJBorden  ECBlum  RH Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;147- 17
Kirkwood  JMIbrahim  JGSondak  VK  et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;182444- 2458
Kirkwood  JMIbrahim  JGSosman  JA  et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;192370- 2380
Spruance  SLReid  JEGrace  MSamore  M Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;482787- 2792
PubMed Link to Article[[XSLOpenURL/10.1128/AAC.48.8.2787-2792.2004]]
Kirkwood  JMManola  JIbrahim  JSondak  VErnstoff  MSRao  UEastern Cooperative Oncology Group, A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;101670- 1677
PubMed Link to Article[[XSLOpenURL/10.1158/1078-0432.CCR-1103-3]]
Wheatley  KIves  NHancock  BGore  MEggermont  ASuciu  S Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? a meta-analysis of the randomised trials. Cancer Treat Rev 2003;29241- 252
PubMed Link to Article[[XSLOpenURL/10.1016/S0305-7372(03)00074-4]]
Pirard  DHeenen  MMelot  CVereecken  P Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004;20843- 48
PubMed Link to Article[[XSLOpenURL/10.1159/000075045]]
André  Tde Gramont  AStudy Group of Clinical Research in Radiotherapies Oncology, Oncology Multidiciplinary Research Group, An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer 2004;4 ((suppl 1)) S22- S28
PubMed Link to Article[[XSLOpenURL/10.3816/CCC.2004.s.004]]
Sondak  VKSosman  JAUnger  JM  et al.  Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine: final analysis of SWOG-9035 [abstract]. J Clin Oncol 2004;227501
Sosman  JAUnger  JMLiu  PY  et al.  HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from Melacine vaccine: an updated analysis of SWOG 9035 [abstract]. Proc Am Soc Clin Oncol 2002;21340a
Sondak  VKLiu  PYTuthill  RJ  et al.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;202058- 2066
PubMed Link to Article[[XSLOpenURL/10.1200/JCO.2002.08.071]]
Sosman  JAUnger  JMLiu  PY  et al. Southwest Oncology Group, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma withan allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;202067- 2075
PubMed Link to Article[[XSLOpenURL/10.1200/JCO.2002.08.072]]
Veronesi  UAdamus  JAubert  C  et al.  A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307913- 916
PubMed Link to Article[[XSLOpenURL/10.1056/NEJM198210073071503]]
Cole  BFGelber  RDKirkwood  JMGoldhirsch  ABarylak  EBorden  E Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996;142666- 2673
Kilbridge  KLCole  BFKirkwood  JM  et al.  Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002;201311- 1318
PubMed Link to Article[[XSLOpenURL/10.1200/JCO.20.5.1311]]
Morton  DLThompson  JFCochran  AJ  et al. MSLT Group, Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;3551307- 1317
PubMed Link to Article[[XSLOpenURL/10.1056/NEJMoa060992]]

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Melanoma